BioAge Labs, Inc.
BIOA
$10.60
$0.171.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.36M | 10.32M | 9.00M | 5.92M | 3.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.36M | 10.32M | 9.00M | 5.92M | 3.86M |
| Cost of Revenue | 87.79M | 83.27M | 73.97M | 68.69M | 70.20M |
| Gross Profit | -77.43M | -72.95M | -64.97M | -62.77M | -66.33M |
| SG&A Expenses | 28.84M | 28.76M | 27.81M | 26.95M | 25.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.63M | 112.03M | 101.78M | 95.64M | 95.19M |
| Operating Income | -106.27M | -101.71M | -92.78M | -89.72M | -91.33M |
| Income Before Tax | -94.46M | -89.93M | -80.61M | -75.79M | -79.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.46 | -89.93 | -80.61 | -75.79 | -79.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.46M | -89.93M | -80.61M | -75.79M | -79.03M |
| EBIT | -106.27M | -101.71M | -92.78M | -89.72M | -91.33M |
| EBITDA | -106.02M | -101.47M | -92.57M | -89.53M | -91.15M |
| EPS Basic | -2.39 | -2.40 | -2.24 | -2.11 | -8.25 |
| Normalized Basic EPS | -1.49 | -1.50 | -1.40 | -1.32 | -5.15 |
| EPS Diluted | -2.39 | -2.40 | -2.24 | -2.11 | -8.25 |
| Normalized Diluted EPS | -1.49 | -1.50 | -1.40 | -1.32 | -5.15 |
| Average Basic Shares Outstanding | 159.35M | 150.36M | 143.73M | 143.56M | 111.21M |
| Average Diluted Shares Outstanding | 159.35M | 150.36M | 143.73M | 143.56M | 111.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |